Clinical Development and Regulatory Approval Risks: Amgen's future success depends heavily on the successful development and regulatory approval of new product candidates, which is a lengthy, expensive, and uncertain process often resulting in failure or significant delays.

Intense Competition and Biosimilar Threats: The biopharmaceutical market is highly competitive, and Amgen faces significant pressure from existing products, new entrants, and the growing threat of biosimilars to its established portfolio, impacting market share and revenue.

Patent Expiry and Loss of Exclusivity Concerns: Many of Amgen's key products are subject to patent protection, and their eventual expiration or challenge by competitors will lead to generic or biosimilar competition, significantly reducing sales and profitability.